Johnson & Johnson (JNJ)vsRegentis Biomaterials Ltd. (RGNT)
JNJ
Johnson & Johnson
$276.32
+3.81%
HEALTHCARE · Cap: $657.68B
RGNT
Regentis Biomaterials Ltd.
$1.37
0.00%
HEALTHCARE · Cap: $8.85M
Smart Verdict
WallStSmart Research — data-driven comparison
JNJ leads profitability with a 16.2% profit margin vs 0.0%. JNJ earns a higher WallStSmart Score of 54/100 (C-).
JNJ
Buy54
out of 100
Grade: C-
RGNT
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-89.3%
Fair Value
$144.28
Current Price
$276.32
$132.04 premium
Intrinsic value data unavailable for RGNT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.7%
Generating 6.4B in free cash flow
Reasonable price relative to book value
Areas to Watch
Trading at 8.2x book value
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.7%.
Bull Case : RGNT
The strongest argument for RGNT centers on Price/Book.
Bear Case : JNJ
The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 41.5x leaves little room for execution misses.
Bear Case : RGNT
The primary concerns for RGNT are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
JNJ profiles as a mature stock while RGNT is a value play — different risk/reward profiles.
JNJ is growing revenue faster at 5.9% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
JNJ scores higher overall (54/100 vs 26/100), backed by strong 16.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Regentis Biomaterials Ltd.
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Regent Assisted Living Inc. is a leading provider of premium assisted living and memory care services, committed to enhancing the quality of life for seniors through customized care and supportive living environments. With a nationwide network of facilities, Regent distinguishes itself through modern amenities and a compassionate, professional staff dedicated to resident well-being. By employing innovative care models and fostering strong community ties, the company consistently elevates its service offerings in a burgeoning senior living market. As the demand for senior care solutions continues to rise, Regent's strategic growth initiatives present a compelling investment opportunity for institutional investors seeking to capitalize on trends within the expanding healthcare sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?